Previous 10 | Next 10 |
MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Timothy E. Morris, the Company’s Chief Financi...
2023-05-01 08:28:49 ET cbdMD ( YCBD ) -40% on pricing $2.8M public offering . First Republic Bank ( FRC ) -35% as JPM pays $10.6B to FDIC for FRC acquisition . TOP Financial Group Limited ( TOP ) -33% . Huadi International Group ( HUDI ) -...
MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that management will participate in the one-on-one meeti...
MONROE TOWNSHIP, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NYSE American: OPTT), a leader in innovative, cost-effective, and autonomous low-carbon marine data, power, and consulting service solutions, today announ...
MONROE TOWNSHIP, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NYSE American: OPTT), a leader in innovative, cost-effective, and autonomous low-carbon marine data, power, and consulting service solutions, is pleased t...
(NewsDirect) Ocean Power Technologies Inc (OPT) CEO Philipp Stratmann joins Natalie Stoberman from the Proactive newsroom to share how the latest deployment of next-generation Wave Energy Converter (WEC) Buoys is opening a new chapter for the company for elevated technology and cost-effective...
MONROE TOWNSHIP, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NYSE American: OPTT), a leader in innovative, cost-effective, and autonomous low-carbon marine data, power, and consulting service solutions, is pleas...
MONROE TOWNSHIP, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), today announced financial results for its fiscal third quarter ended January 31, 2023 (“Q323”), including year-to-date revenue growth of over...
2023-03-07 06:48:14 ET Opthea ( NASDAQ: OPT ) received an A$8.7M ($6.3M) R&D tax credit from the Australian Taxation Office; cash incentive is for costs incurred in the 2021/2022 financial year. The R&D tax incentive credit relates to both Australian and eligi...
MELBOURNE, Australia, March 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.7 million (US$6.3 million) r...
News, Short Squeeze, Breakout and More Instantly...
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail Entitlement Offer follows successful Institutional Entitlement Offer and institutional Placement raising approxima...
Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published in peer-reviewed journal Ophthalmology and Therapy MELBOURNE, Australia and PRINCETON, N.J....